PDCD1 and hereditary clear cell renal cell carcinoma: In addition to metastatic malignancies, adjuvant ICI therapy with anti-PD1 has also been demonstrated to reduce risk of relapse in resected stage III or IV melanoma and resected renal cell carcinoma (11, 12).